precisely defined, but it was not to be. Cloned natural killer cells were also found to display a wide range of phenotypes and target cell preferences. 7 The interferons are probably the major common activation pathway for natural killer cells. A brief incubation with interferons rapidly increases natural killer activity in vitro. Purified populations of natural killer cells can also produce interferon after exposure to inducing agents such as poly Ipoly C, BCG, retinoids, and some target cells.8 In addition, interleukin 2 (T cell growth factor) can directly induce the proliferation of highly purified natural killer populations as well as increase their natural killer activity. 9 The activity of natural killer cells can be inhibited by prostaglandins, histamine, and lipomodulin.01' I Since the first description of natural killer activity in the early 1970s it has been suggested that natural killer cells were an integral part of natural resistance. In conjunction with interferons, which can inhibit viral replication and also recruit cells of the immune system, natural killer cells could play a part in early non-specific attack against virus infected cells. Some evidence that natural killer cells represent a rapidly inducible effector mechanism for eliminating virus infected cells has come from the study of experimental viral infections in animals.2 13 Among 
Doctors and the drug industry: too close for comfort
The drug industry spent £169m promoting its products to doctors in 1983, and the estimated expenditure was almost £200m for 1985.-;That works out at £2500 for each doctor, but almost 80% of the expenditure (£160m) is on general practitioners-over £5000 is thus spent for each general practitioner. In contrast, the NHS spends about £2m refunding expenses incurred by general practitioners attending postgraduate education-less than £70 for each doctor.
The drug industry does, of course, have a perfect right to promote its products. The 14 years and £100m needed on average to produce a new drug mean not only that the company will want to retrieve that money but also that the company is likely to have come to-believe strongly in its product: although it might look like "just another 1 blocker" to the doctor, to the company it is a much valued baby and superior to its competitors. When so much is at stake and so much promotional money is being spent ample room exists for the unscrupulous company or doctor to abuse the relationship that has to exist between doctors and the drug industry. But, more worryingly, room also exists for scrupulous doctors to be overinfluenced by a company's promotion and for a company to be overzealous in its promotion.
The Association of the British Pharmaceutical Industry has a (much criticised) code designed to restrain the overzealous company, and now the Royal College of Physicians has produced guidelines that are supposed to make sure that doctors remain thoroughly "professional" in their relationships with drug companies.' The college-almost, I sense, with regret-has desisted from suggesting that doctors do not accept gifts, hospitality, or travelling expenses from drug companies and instead has produced a code full of words like "acceptable," "moderate," "reasonable," "relevant," and "appropriate." The college admits that judging what is acceptable may be difficult, and the truth is that a weekend in Spain to hear the benefits of a new benzodiazepine might seem quite "reasonable" to one doctor while a ballpoint pen advertising a diuretic will seem "unreasonable" to another. I think that the college may have underestimated the influence of so much promotion, failed to recognise that scrupulous as well as unscrupoulous doctors are at risk, and produced a code that is castrated by the impossibility of definition.
Examples of excess have been visible to all in the past few years and served to prompt the college's report. The Panorama programme that the report quotes showed us doctors travelling to Venice on the Orient Express to hear news of a new non-steroidal anti-inflammatory drug, and a recent story in the newspapers detailed an ex-drug company representative's allegations of how doctors were bribed to enter patients into a scientifically bogus trial.2 Oddly these sporadic reports in the media usually depict the drug companies rather than the doctors as the "baddies." The college's report, however, contains stories in which (anonymous) doctors are clearly the baddies. Many doctors, -it seems, write to drug companies asking for funds to pay for foreign trips, and "one doctor even stated that unless his request was granted he would stop prescribing the company's products." Another group ofdoctors refused to attend a film unless it was "shown with a meal organised at a restaurant of their choice." On another occasion "physicians who all lived in one NHS region" went to a drug company meeting on a "Mediterranean island," which, as the college observes in restrained prose, "could not have the advantage of convenience."
So are a few doctors abusing the system and spoiling it for others, or are these practices widespread? The college report gives no idea of scale but implies that it is small. Mediterranean island trips are not, I suspect, common, but excessive hospitality is. For instance, the code of practice of the ABPI states that "entertainment or hospitality offered . .. should always be secondary to the main purpose of the meeting." Yet I have spoken to many meetings myself where my small "tum" (which could only in the loosest sense be described as educational) has clearly been secondary to the wining and dining offered by drug companies.
One point is thus that the immoderate may be more common than the college recognises. Another point is that the college may underestimate the effect of drug company promotion on doctors' thinking and prescribing. Scientific evidence on this issue is hard to come by, but such massive expenditure by the drug companies must have substantial influence. It is a similar argument to that over promotion of tobacco and alcohol; only in this case doctors tend to be on the other side. Of course, you could not find a doctor who says that he prescribes a drug because ofthe lunches given to him by the company, but it is equally hard to find a consumer who buys a certain brand of rum because of the tropical beaches used to advertise it. Yet marketing data, most of which are rarely made available, show that such promotions do influence sales of their products. Some general pracUtioners have suggested that the powerful influence of drug companies may be their main source of postgraduate education,3 and bias-as every researcher knows-is subtle and pervasive.
Many of the committee's recommendations are hamstrung by the difficulty of definition. One inspired suggestion is that: "a useful criterion of acceptability may be 'Would you be willing to have these arrangements generally known?"' This useful concept acknowledges the important point that independence,is in the eye of the beholder-whether you are seen to be independent is more important than whether you are, or think you are, independent. And at least to the Guardian reading public writing your prescriptions with a drug company pen and drinking even vin ordinaire at drug company expense are sure signs of dependence. The committee does say that it regrets that refreshment at meetings is so often sponsored by pharmaceutical companies and says that as a regular practice it "degrades" the profession. It calls on the Department of Health and Social Security to encourage health authorities to contribute to the support of meetings, but it seems to forget that doctors could pay for themselves. In the absence of a drug company to pay for lunch most doctors still eat.
The committee does better with its recommendations on controlling the content of meetings between doctors and drug company representatives. It recommends against ad hoc meetings and suggests that they should take place only by appointment. It also recommends that at promotional meetings there should always be present an expert capable of independently assessing the claims of the company. A further possibility would have been to suggest a clear system-like that operating in many Swedish hospitals-of determining in advance the scientific and educational value ofwhat is to be presented.4 The aim would be steadily to raise the quality of such meetings. Many drug companies would welcome such a scheme: they do not like dealing in an unseemly trade of ballpoint pens and Italian red wine-they want to make their case and be off.
The college has done well to raise this issue of the relationship between doctors and drug companies, which until now has been discussed more in the lay media than by doctors themselves; and it has produced some useful recommendations. But I believe that this report should be seen as the beginning rather than the end of a debate on how doctors relate to drug companies. A tougher and more specific code-even one with teeth-will eventually be needed. RICHARD 
